Dimensional Fund Advisors LP Lowers Holdings in Supernus Pharmaceuticals, Inc. $SUPN

Dimensional Fund Advisors LP lowered its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 0.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,001,941 shares of the specialty pharmaceutical company’s stock after selling 19,266 shares during the quarter. Dimensional Fund Advisors LP owned approximately 5.24% of Supernus Pharmaceuticals worth $143,462,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Legato Capital Management LLC lifted its holdings in shares of Supernus Pharmaceuticals by 6.0% in the 3rd quarter. Legato Capital Management LLC now owns 22,498 shares of the specialty pharmaceutical company’s stock worth $1,075,000 after buying an additional 1,273 shares during the period. Journey Strategic Wealth LLC purchased a new position in shares of Supernus Pharmaceuticals during the third quarter valued at $213,000. Royce & Associates LP increased its stake in shares of Supernus Pharmaceuticals by 25.4% during the third quarter. Royce & Associates LP now owns 40,765 shares of the specialty pharmaceutical company’s stock valued at $1,948,000 after buying an additional 8,261 shares during the period. Rafferty Asset Management LLC bought a new stake in shares of Supernus Pharmaceuticals in the third quarter valued at about $224,000. Finally, Handelsbanken Fonder AB raised its holdings in shares of Supernus Pharmaceuticals by 3.8% in the third quarter. Handelsbanken Fonder AB now owns 19,016 shares of the specialty pharmaceutical company’s stock valued at $909,000 after acquiring an additional 700 shares in the last quarter.

Insider Activity

In other news, Director Georges Gemayel sold 8,787 shares of the firm’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $53.00, for a total value of $465,711.00. Following the sale, the director directly owned 27,277 shares in the company, valued at approximately $1,445,681. This trade represents a 24.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 710 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $44.44, for a total transaction of $31,552.40. Following the completion of the transaction, the vice president directly owned 14,508 shares in the company, valued at approximately $644,735.52. The trade was a 4.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 43,972 shares of company stock valued at $2,270,833 over the last 90 days. 8.80% of the stock is currently owned by corporate insiders.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $53.67 on Wednesday. The stock’s 50-day moving average is $51.12 and its 200 day moving average is $48.96. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.16 and a 1-year high of $59.68. The company has a market cap of $3.09 billion, a P/E ratio of -78.93, a PEG ratio of 1.68 and a beta of 0.70.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Sunday. Zacks Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Craig Hallum set a $65.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Finally, Stifel Nicolaus lifted their price objective on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a report on Friday, December 19th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Supernus Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $62.17.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.